The Chicago Entrepreneur

Dow Jones Newswires: Japan’s Astellas Pharma to buy Iveric Bio in deal worth $5.9 billion

The Japanese company said it would pay $40.00 per share of Iveric, which booked net loss of $185.2 million and had $534.7 million in net assets in 2022.

Previous post Litecoin price prediction: can bulls pick up new momentum for LTC?
Next post Litecoin price prediction: can bulls pick up new momentum for LTC?